Sermorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) used clinically to stimulate the pulsatile secretion of endogenous Growth Hormone (GH) from the anterior pituitary gland. It is employed in protocols designed to normalize GH levels, particularly when endogenous production has diminished due to aging or chronic stress. It acts as a trophic stimulus for the somatotropic axis.
Origin
Sermorelin’s origin lies in pharmaceutical development aimed at mimicking the action of the natural hypothalamic GHRH peptide. The nomenclature reflects its chemical structure and its functional relationship to Growth Hormone regulation. Its clinical utility is defined by its ability to promote natural, physiological GH release patterns.
Mechanism
The mechanism involves Sermorelin binding specifically to GHRH receptors located on pituitary somatotroph cells. This binding activates the adenylate cyclase pathway, increasing intracellular cyclic AMP (cAMP) levels, which triggers the exocytosis of stored GH into the systemic circulation. Effective protocols leverage the body’s natural nocturnal GH surge by timing administration appropriately.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.